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Background and Aim: We evaluated the
diagnostic performance of an ELISA test for
anti-gliadin IgA and IgG antibodies, which
uses synthetic deamidated gliadin peptides
(anti-gliadin antibodies, AGAs) as coating;
the results were compared with a test that
uses extracted gliadin (AGAe).
Methods: The study was conducted on the
sera of 144 patients suffering from celiac
disease (CD), including 20 patients with IgA
deficiency and 9 who were following a
gluten-free diet (GFD), and 129 controls.
Results: In the 115 CD patients (without IgA
deficiency), the sensitivity of AGAe IgA and
IgG was 32.2 and 60.9%, whereas that of
AGAs IgA and IgG was 59.1 and 72.2%.
The specificity for AGAe IgA and IgG, and
AGAs IgA and IgG was 93.8 and 89.9%,
and 96.9% and 99.2%, respectively. Of the
20 patients with CD and IgA deficiency, 7
tested positive for AGAe IgG and 14 for
AGAs IgG. The test using deamidated
gliadin peptides performed better in terms
of sensitivity and specificity than the AGA
tests with extracted antigen.
Conclusions: The very high specificity of
the AGAs IgG test (99.2%) also suggests
that patients who test positive with this
assay require a thorough followup, even if
the anti-tissue transglutaminase antibodies
(anti-tTG) and anti-endomysial autoantibo-
dies (EMA) assays are negative. J. Clin.
Lab. Anal. 23:165–171, 2009. r 2009
Wiley-Liss, Inc.
Key words: celiac disease; deamidated gliadin peptides; anti-gliadin antibodies; anti-
transglutaminase antibodies
INTRODUCTION
Gluten is a complex protein constituted by the
gliadins and glutenins present in wheat, barley, and
rye. It is the trigger factor of celiac disease (CD), as it
triggers an immune response by the T lymphocytes with
subsequent production of cytokines, anti-gliadin anti-
bodies (AGAs) and anti-tissue transglutaminase anti-
bodies (anti-tTG) (1–4). This cascade of events requires
some predisposing situations, namely (in order of
importance): intake of gluten with the diet, increased
permeability of the intestinal mucosa, a predisposing
genetic makeup characterized by the presence of HLA
molecules of class II DQ2 or DQ8 (5–7). The tTG
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enzyme is a calcium-dependent enzyme able to deami-
date the glutamine residues in which gliadin is rich,
forming glutamic acid residues, which are very efﬁcient
in promoting bonding of the modiﬁed peptides with the
HLA class II DQ2/DQ8 complex (8). The complex
formed by deamidated gliadin peptides, tTG and DQ2/
DQ8 is recognized by speciﬁc intestinal T cells. The end
result of this immune response to gluten is reversible
damage to the enterocytes, with ﬂattening of the
intestinal villi and consequent malabsorption (9–11). A
diagnosis of CD is based on the typical signs and
symptoms associated with the presence of speciﬁc anti-
tTG or anti-endomysial autoantibodies (EMA) (12–14).
AGA testing currently has little diagnostic signiﬁcance,
because the methods used to identify them present lower
levels of sensitivity and speciﬁcity than tests for anti-
tTG or EMA (15,16). However, AGA testing is still
considered useful in patients under 5 years old who test
negative for anti-tTG (17).
The peptide regions of gliadin recognized by the T
lymphocytes of genetically predisposed individuals were
recently identiﬁed (2). These peptides have a relatively
constant aminoacid pattern consisting of the sequence
QPEQPFP, where the triplet PEQ is the epitopic core.
Some studies demonstrate that immunoenzyme tests
(ELISA) that use the sequence QPEQPFP as antigen
have greater sensitivity and speciﬁcity than ELISA tests
with extracted gliadin antigen (18,19).
The purpose of our study was to evaluate the
diagnostic accuracy of a new commercial ELISA test
for the identiﬁcation of AGA IgA and IgG, which uses
synthetic deamidated gliadin peptides as antigen, and to
compare the results with those obtained with tests using
extracted gliadin, and with ELISA and indirect im-
munoﬂuorescence tests for the determination of anti-
tTG and EMA, respectively. We used a large number of
patients with a histological diagnosis of CD for the
study, together with controls.
MATERIAL AND METHODS
Patients
A total of 273 sera were tested: 144 from patients with
a diagnosis of CD, conﬁrmed by a duodenal biopsy in
all cases, and 129 subjects not suffering from CD as
control group.
Of the 144 patients with CD, 115 were newly
diagnosed, 70 of whom were aged 5 years or over
(range, 5–72 years; 32 males and 48 females) and 45 aged
under 5 years (range, 0–4 years; 22 males and 32
females); 20 patients had an absolute IgA deﬁciency
(range, 4–38 years; 8 males and 12 females) and 9 were
celiac patients who had been following a gluten-free diet
(GFD) for 4–17 months (range, 9–46 years; 2 males and
7 females).
The 129 subjects in the control group consisted of 60
healthy blood donors (range 18–52 years; 36 males and
24 females) and of 69 patients affected by different
clinical conditions: 16 lactose intolerance, 24 hepatic
cirrhosis, 15 Crohn’s disease, and 14 ulcerative colitis
(range 2–71 years; 29 males and 40 females).
The patients and controls were selected in 2004–2007
by the Immunopathology and Allergology Department
of Udine Hospital, the Clinical Immunology Depart-
ment of Pordenone Hospital, the Gastroenterology
Department of the Palermo Children’s Hospital, and
the Clinical Pathology Laboratory of S. Dona` di Piave
Hospital. The sera were frozen at 801C and thawed
only once for the performance of tests for speciﬁc AGA
antibodies.
Antibody Assays
In all the sera (CD and controls) the test for AGA IgA
and IgG was conducted with an ELISA test using
gliadin of extracted origin (AGAe) (Quanta-Lite Gliadin
IgA I and IgG I, INOVA Diagnostics, Inc., San Diego,
CA) and with an ELISA test using synthetic deamidated
gliadin peptides (AGAs) containing the sequence PEQ
(Quanta-Lite Gliadin IgA II and IgG II, INOVA). Both
tests were conducted in accordance with the manufac-
turer’s instructions. The same sera were also tested for
anti-tTG IgA with ELISA using recombinant human
antigen (Orgentec Diagnostika, Mainz, Germany); the
EMA IgA test was conducted by the indirect immuno-
ﬂuorescence method on monkey esophagus (INOVA),
and the total IgA assay was conducted by the nephelo-
metric method (Dade Behring, Marburg, Germany).
Sera with an absolute IgA deﬁciency (IgA o0.5 g/L)
were tested for anti-tTG antibodies in the IgG class
(Orgentec; normal value o10AU).
Statistics
The sensitivity and speciﬁcity of the assays for AGAe
and AGAs in the IgA and IgG classes were ﬁrst
calculated using the manufacturers’ cutoffs, and then
using cutoffs corresponding to a speciﬁcity of 95%, as
obtained by receiver operating characteristic (ROC)
curves. When the ROC curves for AGAe and AGAs
were conducted, the 9 patients with CD on a diet and the
20 patients with IgA deﬁciency were excluded. The area
under the curve (AUC), with a 95% conﬁdence interval
(95%CI), was also calculated for each kit. Statistical
analysis was performed using the SPSS 11.0 for
Windows statistical package (SPSS, Chicago, IL).
Two-sided P values of less than 0.05 were considered
signiﬁcant throughout.
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RESULTS
Anti-tTG and EMA Assays
The 70 patients with CD and an age of Z5 years all
tested anti-tTG IgA positive (range 9–4200AU) and
EMA IgA positive (range 1:5–1:5120). Of the 45 patients
with CD agedo5 years, 37 tested anti-tTG IgA positive
(range 8–4200AU) and EMA IgA positive (range
1:5–1:2560), whereas 8 tested anti-tTG and EMA IgA
negative. Of the 20 CD patients with an IgA deﬁciency,
19 tested anti-tTG IgG positive (range 15–4200AU)
and 1 tested anti-tTG IgG negative. The 9 patients on a
GFD tested anti-tTG IgA positive in four cases (range
8–11AU) and negative in ﬁve cases.
All 129 control sera tested negative for anti-tTG IgA
(Table 1).
AGA Assays
At the manufacturer’s cutoff, in the 70 patients with
CD Z5 years the sensitivity of AGAe IgA and IgG was
45.7 and 64.3% and that of AGAs IgA and IgG was 70
and 78.6%. In the 45 patients aged o5 years, the
sensitivity of AGAe IgA and IgG was 11.1 and 55.6%,
and that of AGAs IgA and IgG was 44.4 and 62.2%
(Table 1). On the whole, in the 115 patients with newly
diagnosed CD without an IgA deﬁciency and not on a
GFD, the sensitivity of AGAe IgA and IgG was 32.2
and 60.9% and that of AGAs IgA and IgG was 59.1 and
72.2%.
Of the 20 patients with an IgA deﬁciency, 7 (35%)
tested positive for AGAe IgG and 14 (70%) for
AGAs IgG.
Of the 9 celiac patients on a GFD, none tested positive
for AGAe IgA and 2 (22%) tested positive for AGAe
IgG, while 3 (33%) tested positive for AGAs IgA and 3
(33%) for AGAs IgG (one positive serum for each
antibody class).
The results of the AGAe and AGAs tests in the
control groups showed negligible percentages of false
positives with the manufacturer’s cutoff (20AU), with
two exceptions: of the 24 patients with cirrhosis of the
liver, 4 (16.6%) tested positive for AGAe IgA, and of
the 16 patients with intolerance of cow’s milk, 11
(68.7%) tested positive for AGAe IgG with a high titer
(Table 2).
The overall speciﬁcity evaluated in the control group
was 93.8 and 89.9% for AGAe IgA and IgG and 96.9
and 99.2% for AGAs IgA and IgG (Table 1).
Analysis of the ROC curves showed an area under the
curve (AUC) of 0.812 and 0.849 for AGAe IgA and IgG
and 0.928 and 0.945 for AGAs IgA and IgG (both
differences were statisticaly signiﬁcant: P5 0.04 for IgA
and P5 0.03 for IgG). The cutoffs corresponding to
95% speciﬁcity were 23.3 and 66.2AU, respectively for
AGAe IgA and IgG, and 14.8 and 9.6AU for AGAs
IgA and IgG.
If the sensitivity data between the manufacturer’s
cutoff and a cutoff with predeﬁned speciﬁcity of 95%
are compared, the AGAs tests are clearly superior to
the AGAe tests in the 115 newly diagnosed patients, and
in the 20 cases with an IgA deﬁciency (only for the
class IgG tests) and the 9 patients following a diet
(Table 3).
In the 14 anti-tTG negative patients (8 with a
diagnosiso5 years, 5 on a diet, and 1 patient with an
IgA deﬁciency) a signiﬁcant difference in sensitivity was
observed between the IgA AGAe and IgA AGAs tests
(0 and 4 positive cases, respectively), whereas for the
IgG class tests, the sensitivity did not vary signiﬁcantly;
TABLE 1. Results of the Test for Anti-Gliadin Antibodies IgA and IgG with extracted antigen (AGAe) and With Synthetic Peptide
Antigen (AGAs) in Patients Suffering From Celiac Disease and Controls
No.
Anti-tTG
pos
Anti-tTG
neg
IgA AGAe
N (%)
IgG AGAe
N (%)
IgA AGAs
N (%)
IgG AGAs
N (%)
(A) Celiac patients
Z5 years 70 70 0 32 (46%) 45 (64%) 49 (70%) 55 (79%)
o5 years 45 37 8 5 (11%) 25 (56%) 20 (44%) 28 (62%)
IgA deﬁcient 20 a19 1 ND 7 (35%) ND 14 (70%)
On gluten free diet 9 4 5 0 2 (22%) 3 (33%) 3 (33%)
Total 144 130 14 37 (26%) 79 (55%) 72 (50%) 100 (69%)
(B) Controls
Healthy 60 0 60 1 (2%) 1 (2%) 2 (3%) 0
Milk intolerance children 16 0 16 2 (12%) 11 (69%) 1 (6%) 1 (6%)
Hepatic cirrhosis 24 0 24 4 (17%) 0 1 (4%) 0
IBD (15 Crohn’s disease, 14 UC) 29 0 29 1 (3%) 1 (3%) 0 0
Total 129 0 129 8 (6%) 13 (10%) 4 (3%) 1 (1%)
The cutoff considered was that recommended by the manufacturer (20AU for the four tests).
aPatients with an IgA deﬁciency were evaluated with the anti-tTG IgG test. IBD: inﬂammatory bowel disease UC: ulcerative colitis.
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a substantial increase in sensitivity emerged for AGAs
IgG with the cutoff obtained from ROC curves
(Table 4).
DISCUSSION
The excellent diagnostic performance of tests for anti-
tTG and EMA antibodies has enabled the hidden part
of the celiac iceberg to be identiﬁed in recent years
(20,21). The current prevalence of CD in the Western
countries is estimated at between 1:80 and 1:100
(16,20–24). Identiﬁcation of anti-tTG and EMA anti-
bodies as a marker for CD has caused AGA to lose the
diagnostic role they had held since the early 80s (25).
Today, the clinical usefulness of AGA is restricted to
speciﬁc diagnostic ambits: in the early years of life
(possible negativity for anti-tTG), in patients with an
IgA deﬁciency (determination of AGA IgG in associa-
tion with anti-tTG IgG), and in all cases in which anti-
tTG or EMA antibodies do not give clear results (i.e.,
borderline values) (26,27). However, the use of the
quantitative ELISA assay to test for AGA IgA and IgG
is still very widespread. Statistics supplied by the
European Diagnostic Manufacturers’ Association de-
monstrate that expenditure on the purchase of AGA
assays in 2006 was only slightly less than the total
expenditure on EMA and anti-tTG tests. There are
several reasons for this: little knowledge of the greater
diagnostic accuracy of the new tests, inappropriate
requests that involve the performance of AGA in
association with anti-tTG and EMA tests, and adminis-
trative aspects (reimbursement of the tests). The
persistence of demand for AGA tests has led some
manufacturers to develop new AGA ELISA tests that
use deamidated gliadin peptides as antigen. Some
studies have demonstrated that the immune response
to gliadin in CD patients is directed against limited
portions of the protein structure, and that the epitopic
core of these sequences is constituted by the tripeptide
PEQ (28,29). The aim of our study was to compare the
diagnostic performance of a new ELISA test using
synthetic gliadin peptides and an ELISA test using
extracted gliadin for assaying AGA IgA and IgG in a
group of celiac patients and controls with different
clinical and serological characteristics.
The speciﬁcity evaluation, conducted on a hetero-
geneous population of normal subjects and patients with
disorders of the gastroenteric tract other than CD,
demonstrates that AGAs tests are far more speciﬁc (IgA
96.9%, IgG 99.2%) than the analogous AGAe tests
(IgA 93.8%, IgG 89.9%). In particular, the AGAe IgG
test gave false positives with high titers in 11 out of 16
cases in pediatric patients with milk intolerance, whereas
only one of these patients tested AGAs IgG positive.
This aspect is important for two reasons, ﬁrstly because
it demonstrates that patients with intestinal disorders
other than CD can synthesize high titers of AGA whose
epitopic targets are different from those of the AGA of
CD patients. The second aspect is clinically signiﬁcant
because the use of AGA IgG is recommended speciﬁ-
cally in pediatric patients where a negative anti-tTG IgA
test may not rule out CD.
As regards sensitivity, our study demonstrates the
clear superiority of AGAs over AGAe in all categories
of CD patients studied. In particular, the excellent
sensitivity of the AGAs IgG test should be noted; with
the cutoff at 9.6AU (determined on the basis of the
ROC curves with 95% speciﬁcity) the test was positive
TABLE 2. Antibody Concentration (With False-Positive Results Shown in Bold) of Extracted AGA IgA and IgG (AGAe) and
AGA Synthetic Peptide (AGAs) Tests, in Children With Milk Intolerance
Milk intolerance
children Age IgA AGAe 420AU IgG AGAe 420AU IgA AGAs 420AU IgG AGAs 420AU
1 5 140.00 115.15 23.96 27.90
2 5 4.77 26.04 3.90 6.81
3 6 2.12 7.23 2.03 8.70
4 7 3.74 35.52 2.06 6.00
5 6 12.18 104.91 2.95 5.42
6 6 14.50 114.06 3.31 6.64
7 6 13.54 66.74 2.47 9.58
8 6 25.65 114.39 5.02 17.43
9 14 9.68 51.53 6.14 6.86
10 10 7.61 84.58 2.60 6.01
11 5 2.11 4.60 2.30 5.68
12 6 2.49 12.96 2.85 8.13
13 5 6.67 64.19 2.36 5.87
14 7 9.46 18.70 5.53 10.62
15 6 6.35 40.66 3.11 6.81
16 6 2.63 5.77 2.41 6.01
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in 94.3% of the 70 CD patients aged 45 years and in
80% of the 45 CD patients aged o5 years (8 of these
were anti-tTG IgA negative).
An important factor is the role of AGA class IgG in
patients with an IgA deﬁciency. In the 20 patients with an
IgA deﬁciency, the AGAs IgG test was positive in 70% of
cases as against 35% for AGAe IgG. Patients with an IgA
deﬁciency (total IgA o0.5mg/L) are known to have a
signiﬁcantly higher risk than the normal population of
developing CD and, in the absence of IgA, it is necessary
to test for class IgG antibodies. However, recent studies
report unfavorable data relating to the performance of
commercial anti-tTG IgG tests in terms of both sensitivity
and speciﬁcity (21). The possibility of combining the anti-
tTG IgG test with a sensitive, speciﬁc AGA IgG test may
therefore prove very useful in diagnostic practice (30). The
diagnostic usefulness of the AGAs IgA and IgG tests was
demonstrated in the group of 14 CD patients who tested
anti-tTG IgA or anti-tTG IgG negative. These data
conﬁrm that the AGA test may have a diagnostic role in
all cases in which there is a valid clinical suspicion of CD,
but the anti-tTG or EMA tests are negative. Our series of
CD patients following a GFD includes too few patients to
yield deﬁnite conclusions. Nevertheless, we have observed
in these patients a greater sensitivity of AGAs than
AGAe. Positivity with a low titer of AGAs could suggest
that the diet should be reassessed, even if the anti-tTG test
is negative: the introduction of small quantities of gluten
into the diet of celiac patients on a GFD could damage
the intestinal mucosa, and be associated with positivity for
AGA but not for anti-tTG (31).
To sum up, our study conﬁrms the preliminary data
published by other authors, in which it is evident that
AGA tests using deamidated gliadin peptides give
excellent results in the diagnosis of CD patients
(18,19,32). Our very heterogeneous case study demon-
strates the particular diagnostic efﬁciency of the AGAs
class IgG tests. In view of its performance in all groups
of patients, AGAs IgG demonstrates high sensitivity,
suggesting its use in routine diagnostic practice in all
cases in which anti-tTG tests are inconclusive. The very
high speciﬁcity of the test (99.2%) also suggests that a
thorough followup is necessary if the values are even
slightly above the cutoff, even if the other markers are
negative, because the patient may develop CD. This test
could therefore be used together with other laboratory
tests to increase the diagnostic sensitivity of tests for
CD, bearing in mind that in the coming years, cases of
CD presenting a typical picture from the clinical and
serological standpoint will decline as a result of the
greater attention paid to this disorder by pediatricians,
gastroenterologists, and general practitioners, whereas
cases with atypical or mild symptoms will increase.
Pathologists will have to interpret more and more often
anti-tTG/EMA tests that are negative or present a low
titer in patients with vague clinical symptoms, and will
consequently require additional tests that either support
the diagnosis or rule out the disease.
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